Skip to main content
Erschienen in: Clinical Journal of Gastroenterology 1/2024

30.11.2023 | Case Report

Detection of hepatocellular carcinoma during Fontan-associated liver disease follow-up: a report of three cases

verfasst von: Hideki Onishi, Norihisa Toh, Teiji Akagi, Kenji Baba, Yasuhiro Kotani, Akinobu Takaki, Shingo Kasahara, Hiroshi Ito

Erschienen in: Clinical Journal of Gastroenterology | Ausgabe 1/2024

Einloggen, um Zugang zu erhalten

Abstract

We herein demonstrate three patients diagnosed with early hepatocellular carcinoma (HCC) during follow-up for Fontan-associated liver disease (FALD). Case 1: Twenty-one years after undergoing the Fontan procedure, a 26-year-old female was diagnosed with FALD. At the initial consultation, her serum alpha-fetoprotein (AFP) levels were markedly elevated, and dynamic enhanced computed tomography (CT) revealed HCC measuring 40 mm in diameter. She underwent partial hepatectomy. Ten months later, she underwent conventional transcatheter arterial chemoembolization (cTACE) for recurrent HCC near the resected hepatic stump as a curative treatment. Case 2: Twenty-one years after undergoing the Fontan procedure, a 25-year-old male was diagnosed with FALD and underwent HCC surveillance every 6 months. Thirteen months after the initial consultation, dynamic enhanced CT revealed HCC measuring 10 mm in diameter. He received cTACE as a curative treatment. Case 3. Twenty-eight years after undergoing the Fontan procedure, a 37-year-old male was diagnosed with FALD and underwent HCC surveillance every 3 months. Fourteen months later, abdominal ultrasonography (US) revealed HCC measuring 13 mm in diameter. He received radiofrequency ablation. These cases showed that HCC surveillance using abdominal US and AFP measurements in patients with FALD enables the detection of HCC and increases the chance of a cure.
Literatur
1.
Zurück zum Zitat d’Udekem Y, Iyengar AJ, Cochrane AD, et al. The Fontan procedure: contemporary techniques have improved long-term outcomes. Circulation. 2007;116:I157–64.CrossRefPubMed d’Udekem Y, Iyengar AJ, Cochrane AD, et al. The Fontan procedure: contemporary techniques have improved long-term outcomes. Circulation. 2007;116:I157–64.CrossRefPubMed
2.
Zurück zum Zitat Khairy P, Fernandes SM, Mayer JE, et al. Long-term survival, modes of death, and predictors of mortality in patients with Fontan surgery. Circulation. 2008;117:85–92.CrossRefPubMed Khairy P, Fernandes SM, Mayer JE, et al. Long-term survival, modes of death, and predictors of mortality in patients with Fontan surgery. Circulation. 2008;117:85–92.CrossRefPubMed
3.
Zurück zum Zitat Stanton RE, Lurie PR, Lindesmith GG, et al. The Fontan procedure for tricuspid atresia. Circulation. 1981;64:II140–6.PubMed Stanton RE, Lurie PR, Lindesmith GG, et al. The Fontan procedure for tricuspid atresia. Circulation. 1981;64:II140–6.PubMed
4.
Zurück zum Zitat Ghaferi AA, Hutchins GM. Progression of liver pathology in patients undergoing the Fontan procedure: chronic passive congestion, cardiac cirrhosis, hepatic adenoma, and hepatocellular carcinoma. J Thorac Cardiovasc Surg. 2005;129:1348–52.CrossRefPubMed Ghaferi AA, Hutchins GM. Progression of liver pathology in patients undergoing the Fontan procedure: chronic passive congestion, cardiac cirrhosis, hepatic adenoma, and hepatocellular carcinoma. J Thorac Cardiovasc Surg. 2005;129:1348–52.CrossRefPubMed
5.
Zurück zum Zitat Rodriguez De Santiago E, Téllez L, Guerrero A, et al. Hepatocellular carcinoma after Fontan surgery: a systematic review. Hepatol Res. 2021;51:116–34.CrossRefPubMed Rodriguez De Santiago E, Téllez L, Guerrero A, et al. Hepatocellular carcinoma after Fontan surgery: a systematic review. Hepatol Res. 2021;51:116–34.CrossRefPubMed
6.
Zurück zum Zitat Egbe AC, Poterucha JT, Warnes CA, et al. Hepatocellular carcinoma after Fontan operation: multicenter case series. Circulation. 2018;138:746–8.CrossRefPubMed Egbe AC, Poterucha JT, Warnes CA, et al. Hepatocellular carcinoma after Fontan operation: multicenter case series. Circulation. 2018;138:746–8.CrossRefPubMed
7.
Zurück zum Zitat Endo M, Soroida Y, Sato M, et al. Ultrasound evaluation of liver stiffness: accuracy of ultrasound imaging for the prediction of liver cirrhosis as evaluated using a liver stiffness measurement. J Med Dent Sci. 2017;64:27–34.PubMed Endo M, Soroida Y, Sato M, et al. Ultrasound evaluation of liver stiffness: accuracy of ultrasound imaging for the prediction of liver cirrhosis as evaluated using a liver stiffness measurement. J Med Dent Sci. 2017;64:27–34.PubMed
8.
Zurück zum Zitat Shimizu H, Endo S, Natsugoe S, et al. Thoracic and cardiovascular surgery in Japan in 2016: annual report by The Japanese Association for Thoracic Surgery. Gen Thorac Cardiovasc Surg. 2019;67:377–411.CrossRefPubMed Shimizu H, Endo S, Natsugoe S, et al. Thoracic and cardiovascular surgery in Japan in 2016: annual report by The Japanese Association for Thoracic Surgery. Gen Thorac Cardiovasc Surg. 2019;67:377–411.CrossRefPubMed
9.
Zurück zum Zitat Akintoye E, Miranda WR, Veldtman GR, et al. National trends in Fontan operation and in-hospital outcomes in the USA. Heart. 2019;105:708–14.CrossRefPubMed Akintoye E, Miranda WR, Veldtman GR, et al. National trends in Fontan operation and in-hospital outcomes in the USA. Heart. 2019;105:708–14.CrossRefPubMed
10.
Zurück zum Zitat Kudo M, Izumi N, Kokudo N, et al. Report of the 21st nationwide follow-up survey of primary liver cancer in Japan (2010–2011). Hepatol Res. 2021;51:355–405.CrossRefPubMed Kudo M, Izumi N, Kokudo N, et al. Report of the 21st nationwide follow-up survey of primary liver cancer in Japan (2010–2011). Hepatol Res. 2021;51:355–405.CrossRefPubMed
11.
Zurück zum Zitat Marrero JA, Kulik LM, Sirlin CB, et al. Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the american association for the study of liver diseases. Hepatology. 2018;68:723–50.CrossRefPubMed Marrero JA, Kulik LM, Sirlin CB, et al. Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the american association for the study of liver diseases. Hepatology. 2018;68:723–50.CrossRefPubMed
12.
Zurück zum Zitat Bolondi L. Screening for hepatocellular carcinoma in cirrhosis. J Hepatol. 2003;39:1076–84.CrossRefPubMed Bolondi L. Screening for hepatocellular carcinoma in cirrhosis. J Hepatol. 2003;39:1076–84.CrossRefPubMed
13.
Zurück zum Zitat Kim CK, Lim JH, Lee WJ. Detection of hepatocellular carcinomas and dysplastic nodules in cirrhotic liver: accuracy of ultrasonography in transplant patients. J Ultrasound Med. 2001;20:99–104.CrossRefPubMed Kim CK, Lim JH, Lee WJ. Detection of hepatocellular carcinomas and dysplastic nodules in cirrhotic liver: accuracy of ultrasonography in transplant patients. J Ultrasound Med. 2001;20:99–104.CrossRefPubMed
14.
Zurück zum Zitat Gupta S, Bent S, Kohwles J. Test characteristics of α-fetoprotein for detecting hepatocellular carcinoma in patients with hepatitis C. A systematic review and critical analysis. Ann Intern Med. 2003;139:46–50.CrossRefPubMed Gupta S, Bent S, Kohwles J. Test characteristics of α-fetoprotein for detecting hepatocellular carcinoma in patients with hepatitis C. A systematic review and critical analysis. Ann Intern Med. 2003;139:46–50.CrossRefPubMed
15.
Zurück zum Zitat Tayob N, Lok ASF, Do KA, et al. Improved detection of hepatocellular carcinoma by using a longitudinal alpha-fetoprotein screening algorithm. Clin Gastroenterol Hepatol. 2016;14(469–75): e2. Tayob N, Lok ASF, Do KA, et al. Improved detection of hepatocellular carcinoma by using a longitudinal alpha-fetoprotein screening algorithm. Clin Gastroenterol Hepatol. 2016;14(469–75): e2.
16.
Zurück zum Zitat Rosenbaum J, Vrazas J, Lane GK, et al. Cardiac cirrhosis and hepatocellular carcinoma in a 13-year-old treated with doxorubicin microbead transarterial chemoembolization. J Paediatr Child Health. 2012;48:E140–3.CrossRefPubMed Rosenbaum J, Vrazas J, Lane GK, et al. Cardiac cirrhosis and hepatocellular carcinoma in a 13-year-old treated with doxorubicin microbead transarterial chemoembolization. J Paediatr Child Health. 2012;48:E140–3.CrossRefPubMed
17.
Zurück zum Zitat Yamada K, Shinmoto H, Kawamura Y, et al. Transarterial embolization for pediatric hepatocellular carcinoma with cardiac cirrhosis. Pediatr Int. 2015;57:766–70.CrossRefPubMed Yamada K, Shinmoto H, Kawamura Y, et al. Transarterial embolization for pediatric hepatocellular carcinoma with cardiac cirrhosis. Pediatr Int. 2015;57:766–70.CrossRefPubMed
18.
Zurück zum Zitat Saliba T, Dorkhom S, O’Reilly EM, et al. Hepatocellular carcinoma in two patients with cardiac cirrhosis. Eur J Gastroenterol Hepatol. 2010;22:889–91.CrossRefPubMed Saliba T, Dorkhom S, O’Reilly EM, et al. Hepatocellular carcinoma in two patients with cardiac cirrhosis. Eur J Gastroenterol Hepatol. 2010;22:889–91.CrossRefPubMed
19.
Zurück zum Zitat European Association for the Study of the Liver. EASL clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2018;69:182–236.CrossRef European Association for the Study of the Liver. EASL clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2018;69:182–236.CrossRef
20.
Zurück zum Zitat Kokudo N, Takemura N, Hasegawa K, et al. Clinical practice guidelines for hepatocellular carcinoma: the Japan Society of Hepatology 2017 (4th JSH-HCC guidelines) 2019 update. Hepatol Res. 2019;49:1109–13.CrossRefPubMed Kokudo N, Takemura N, Hasegawa K, et al. Clinical practice guidelines for hepatocellular carcinoma: the Japan Society of Hepatology 2017 (4th JSH-HCC guidelines) 2019 update. Hepatol Res. 2019;49:1109–13.CrossRefPubMed
Metadaten
Titel
Detection of hepatocellular carcinoma during Fontan-associated liver disease follow-up: a report of three cases
verfasst von
Hideki Onishi
Norihisa Toh
Teiji Akagi
Kenji Baba
Yasuhiro Kotani
Akinobu Takaki
Shingo Kasahara
Hiroshi Ito
Publikationsdatum
30.11.2023
Verlag
Springer Nature Singapore
Erschienen in
Clinical Journal of Gastroenterology / Ausgabe 1/2024
Print ISSN: 1865-7257
Elektronische ISSN: 1865-7265
DOI
https://doi.org/10.1007/s12328-023-01892-w

Weitere Artikel der Ausgabe 1/2024

Clinical Journal of Gastroenterology 1/2024 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

29.05.2024 Herzinfarkt Nachrichten

Bei Menschen mit Typ-2-Diabetes sind die Chancen, einen Myokardinfarkt zu überleben, in den letzten 15 Jahren deutlich gestiegen – nicht jedoch bei Betroffenen mit Typ 1.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.